RxDoctor Payments Data

Jignasa Patel, MD

Internal Medicine · Greenville, NCNPI 1710984752

Payments from drug & device makers

$788in general payments, 2019–2025

Across 29 payments — averaging $27.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$187
  • Boston Scientific$184
  • Corvista Health, Inc.$94
  • Novo Nordisk$73
  • E.r. Squibb & Sons, L.L.C.$43
  • Irhythm Technologies, Inc.$41
  • plus $166 from 8 others

What the payments were for

  • Food & beverage$71390%
  • Education$7510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$425,024
Medicare patients
510
Services billed
18,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$78,391
JanuviaSitagliptin Phosphate64$67,071
OzempicSemaglutide55$57,931
ArexvyRsvpref3 Antigen/As01e/Pf175$54,269
LinzessLinaclotide51$42,399
Janumet XrSitagliptin Phos/Metformin Hcl31$33,775
MyrbetriqMirabegron28$22,514
TradjentaLinagliptin17$18,521
CreonLipase/Protease/Amylase14$14,631
TrulicityDulaglutide12$11,029
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,523
Atorvastatin Calcium802$7,951
BelsomraSuvorexant17$7,184
XareltoRivaroxaban13$6,897
Levothyroxine Sodium566$6,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$78,39187 claims
AbbVieLinzess, Creon, Synthroid$32$59,616111 claims
Novo NordiskOzempic$73$57,93155 claims
Astellas Pharma US IncMyrbetriq$187$22,51428 claims
Lilly USA, LLCTrulicity$13$11,02912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →